论文部分内容阅读
目的:探讨香菇多糖联合化疗治疗中晚期老年非小细胞肺癌(NSCLC)患者的临床应用效果。方法:以2012年12月-2015年1月本院收治的140例老年NSCLC患者为研究对象,将其随机分为观察组和对照组。给予对照组患者常规化疗进行治疗,观察组患者则在化疗基础上联合香菇多糖进行治疗。对比分析两组患者的临床治疗效果。结果:术后随访8个月,观察组患者生活质量改善情况明显优于对照组,差异具有统计学意义(P<0.05);两组患者治疗有效率、疾病控制率对比,差异无统计学意义(P>0.05);观察组患者不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论:香菇多糖联合化疗治疗中晚期老年非小细胞肺癌(NSCLC)有着较好的临床应用效果,能提升患者生活质量,且副毒作用少,安全性高。
Objective: To investigate the clinical application of lentinan plus chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: A total of 140 elderly patients with NSCLC admitted to our hospital from December 2012 to January 2015 were randomly divided into observation group and control group. The patients in the control group were treated with conventional chemotherapy. The patients in the observation group were treated with lentinan on the basis of chemotherapy. Comparative analysis of two groups of patients with clinical effects. Results: After 8 months of follow-up, the quality of life in the observation group was significantly better than that in the control group (P <0.05). There was no significant difference between the two groups in the treatment efficiency and disease control rate (P> 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group, with significant difference (P <0.05). Conclusion: Lentinan combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) has a good clinical application effect, which can improve patients’ quality of life with less side effects and high safety.